冠心病介入诊疗最新临床研究进展

霍勇; 郑博; 刘耀琨

doi:10.13201/j.issn.1001-1439.2023.05.001

冠心病介入诊疗最新临床研究进展

- 1.
  北京大学第一医院心血管内科(北京，100034)
- 2.
  北京大学第一医院心血管病研究所

详细信息

通讯作者: 霍勇，E-mail：huoyong@263.net.cn

中图分类号: R541.4

收稿日期: 2023-03-27

刊出日期: 2023-05-13

The latest clinical research progress of interventional diagnosis and treatment in coronary heart disease

- 1.
  Department of Cardiovascular Medicine, Peking University First Hospital, Beijing, 100034, China
- 2.
  Institute of Cardiovascular Disease, The First Hospital of Peking University

More Information

Corresponding author: HUO Yong, E-mail: huoyong@263.net.cn

Received Date: 27 March 2023

Publish Date: 13 May 2023

摘要

摘要: 随着医疗技术突飞猛进的发展，介入治疗技术、理念等时刻都在更新与进步。通过检索近几年发表于医学综合类及心血管专类顶级学术期刊的临床研究，从腔内影像学和功能学评估、治疗策略以及介入器械等方面，对冠心病介入的最新诊疗进行分类盘点。
- 冠心病 /
- 经皮冠状动脉介入 /
- 腔内影像学 /
- 功能学评估
Abstract: With the rapid development of medicine, interventional techniques and concepts are all keeping updating constantly. By searching the recent clinical studies published in the top-class international journals, we reviewed the latest research progress in the diagnosis and treatment of coronary artery disease(CAD) intervention from the aspects of intravascular imaging or coronary physiological assessment, treatment strategies and interventional devices.
- coronary heart disease /
- percutaneous coronary intervention /
- endovascular imaging /
- functional evaluation

HTML全文

参考文献(43)

[1]	Andell P, Karlsson S, Mohammad MA, et al. Intravascular ultrasound guidance is associated with better outcome in patients undergoing unprotected left main coronary artery stenting compared with angiography guidance alone[J]. Circ Cardiovasc Interv, 2017, 10(5): 100.
[2]	Kim JS, Kang TS, Mintz GS, et al. Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses[J]. JACC Cardiovasc Interv, 2013, 6(4): 369-376. doi: 10.1016/j.jcin.2012.11.009
[3]	Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications[J]. JACC Cardiovasc Interv, 2009, 2(11): 1035-1046. doi: 10.1016/j.jcin.2009.06.019
[4]	Lee JM, Choi KH, Song YB, et al. Intravascular imaging-guided or angiography-guided complex PCI[J]. New Engl J Med, 2023 Mar 5. doi: 10.1056/NEJMoa2216607.
[5]	折振兴, 于波. 易损斑块成像进展[J]. 中国介入心脏病学杂志, 2022, 30(3): 208-213. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJXB202203009.htm
[6]	Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion(the EROSION study)[J]. Eur Heart J, 2017, 38(11): 792-800.
[7]	Jia H, Dai J, He L, et al. EROSION Ⅲ: A multicenter RCT of OCT-guided reperfusion in STEMI with early infarct artery patency[J]. JACC Cardiovasc Interv, 2022, 15(8): 846-856. doi: 10.1016/j.jcin.2022.01.298
[8]	Park SJ, Kang SJ, Ahn JM, et al. Visual-functional mismatch between coronary angiography and fractional flow reserve[J]. JACC Cardiovasc Interv, 2012, 5(10): 1029-1036. doi: 10.1016/j.jcin.2012.07.007
[9]	Toth G, Hamilos M, Pyxaras S, et al. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses[J]. Eur Heart J, 2014, 35(40): 2831-2838. doi: 10.1093/eurheartj/ehu094
[10]	Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. New Engl J Med, 2009, 360(3): 213-224. doi: 10.1056/NEJMoa0807611
[11]	Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve[J]. N Engl J Med, 2018, 379(3): 250-259. doi: 10.1056/NEJMoa1803538
[12]	Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(3): e18-e114.
[13]	Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14): 1289-1367. doi: 10.1093/eurheartj/ehaa575
[14]	《中国经皮冠状动脉介入治疗指南(2016)》正式发布[J]. 中国介入心脏病学杂志, 2016, 24(6): 315.
[15]	Li J, Gong Y, Wang W, et al. Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR[J]. Cardiovasc Res, 2020, 116(7): 1349-1356. doi: 10.1093/cvr/cvz289
[16]	Tang CX, Liu CY, Lu MJ, et al. CT FFR for ischemia-specific CAD with a new computational fluid dynamics algorithm: A Chinese Multicenter Study[J]. JACC Cardiovasc Imaging, 2020, 13(4): 980-990. doi: 10.1016/j.jcmg.2019.06.018
[17]	Götberg M, Berntorp K, Rylance R, et al. 5-Year Outcomes of PCI guided by measurement of instantaneous wave-free ratio versus fractional flow reserve[J]. JACC, 2022, 79(10): 965-974. doi: 10.1016/j.jacc.2021.12.030
[18]	Tu S, Westra J, Yang J, et al. Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR Pilot Study[J]. JACC Cardiovasc Intervent, 2016, 9(19): 2024-2035. doi: 10.1016/j.jcin.2016.07.013
[19]	余作忠, 杨人强. 基于影像学的血流储备分数衍生指标研究进展[J]. 中国介入心脏病学杂志, 2021, 29(3): 164-168. doi: 10.3969/j.issn.1004-8812.2021.03.010
[20]	Song L, Xu B, Tu S, et al. 2-year outcomes of angiographic quantitative flow ratio-guided coronary interventions[J]. J Am Coll Cardiol, 2022, 80(22): 2089-2101. doi: 10.1016/j.jacc.2022.09.007
[21]	Xu B, Tu S, Song L, et al. Angiographic quantitative flow ratio-guided coronary intervention(FAVOR Ⅲ China): a multicentre, randomised, sham-controlled trial[J]. Lancet, 2021, 398(10317): 2149-2159. doi: 10.1016/S0140-6736(21)02248-0
[22]	Koo BK, Hu X, Kang J, et al. Fractional flow reserve or intravascular ultrasonography to guide PCI[J]. N Engl J Med, 2022, 387(9): 779-789. doi: 10.1056/NEJMoa2201546
[23]	Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single-center trial[J]. JACC Cardiovasc Interv, 2020, 13(1): 49-58. doi: 10.1016/j.jcin.2019.09.034
[24]	Kedhi E, Berta B, Roleder T, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial[J]. Eur Heart J, 2021, 42(45): 4671-4679. doi: 10.1093/eurheartj/ehab433
[25]	沈迎, 王伟民, 张奇, 等. 经皮冠状动脉介入治疗2022年度临床研究进展[J]. 中国介入心脏病学杂志, 2023, 31(1): 25-32. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJXB202301005.htm
[26]	Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABG for left main coronary disease[J]. N Engl J Med, 2019, 381(19): 1820-1830. doi: 10.1056/NEJMoa1909406
[27]	Thuijs D, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial[J]. Lancet, 2019, 394(10206): 1325-1334. doi: 10.1016/S0140-6736(19)31997-X
[28]	Park DW, Ahn JM, Park H, et al. Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the PRECOMBAT Trial[J]. Circulation, 2020, 141(18): 1437-1446. doi: 10.1161/CIRCULATIONAHA.120.046039
[29]	Tam DY, Fang J, Rocha RV, et al. Real-world examination of revascularization strategies for left main coronary disease in Ontario, Canada[J]. JACC Cardiovasc Interv, 2023, 16(3): 277-288. doi: 10.1016/j.jcin.2022.10.016
[30]	Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-Ⅱ(Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions)trial[J]. J Am Coll Cardiol, 2011, 57(8): 914-920. doi: 10.1016/j.jacc.2010.10.023
[31]	Chen X, Li X, Zhang JJ, et al. 3-year outcomes of the DKCRUSH-V trial comparing DK Crush with provisional stenting for left main bifurcation lesions[J]. JACC Cardiovasc Interv, 2019, 12(19): 1927-1937. doi: 10.1016/j.jcin.2019.04.056
[32]	Chen SL, Sheiban I, Xu B, et al. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study(Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts)[J]. JACC Cardiovasc Interv, 2014, 7(11): 1266-1276. doi: 10.1016/j.jcin.2014.04.026
[33]	Kan J, Zhang JJ, Sheiban I, et al. 3-year outcomes after 2-stent with provisional stenting for complex bifurcation lesions defined by DEFINITION Criteria[J]. JACC Cardiovasc Interv, 2022, 15(13): 1310-1320. doi: 10.1016/j.jcin.2022.05.026
[34]	Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional Flow Reserve-Guided PCI as compared with coronary bypass surgery[J]. N Engl J Med, 2022, 386(2): 128-137. doi: 10.1056/NEJMoa2112299
[35]	Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J]. N Engl J Med, 2009, 360(10): 961-972. doi: 10.1056/NEJMoa0804626
[36]	Indolfi C, De Rosa S, Colombo A. Bioresorbable vascular scaffolds-basic concepts and clinical outcome[J]. Nat Rev Cardiol, 2016, 13(12): 719-729. doi: 10.1038/nrcardio.2016.151
[37]	Ali ZA, Gao R, Kimura T, et al. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB Randomized Trials[J]. Circulation, 2018, 137(5): 464-479. doi: 10.1161/CIRCULATIONAHA.117.031843
[38]	Kereiakes DJ, Ellis SG, Metzger DC, et al. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB Ⅲ Trial[J]. Circulation, 2019, 140(23): 1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584
[39]	Song L, Xu B, Chen Y, et al. Thinner strut sirolimus-eluting BRS Versus EES in patients with coronary artery disease: FUTURE-Ⅱ Trial[J]. JACC Cardiovasc Interv, 2021, 14(13): 1450-1462. doi: 10.1016/j.jcin.2021.04.048
[40]	Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO(Balloon Elution and Late Loss Optimization)study[J]. J Am Coll Cardiol, 2012, 60(24): 2473-2480. doi: 10.1016/j.jacc.2012.09.020
[41]	Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis[J]. Circulation, 2009, 119(23): 2986-2994. doi: 10.1161/CIRCULATIONAHA.108.839282
[42]	陈韵岱, 王建安, 刘斌, 等. 药物涂层球囊临床应用中国专家共识[J]. 中国介入心脏病学杂志, 2016, 24(2): 61-67. doi: 10.3969/j.issn.1004-8812.2016.02.001
[43]	Xu K, Fu G, Tong Q, et al. Biolimus-coated balloon in small-vessel coronary artery disease: the BIO-RISE CHINA Study[J]. JACC Cardiovasc Interv, 2022, 15(12): 1219-1226. doi: 10.1016/j.jcin.2022.03.024